Levomepromazine

Jump to: navigation, search
Levomepromazine
Levomepromazine2DCSD.png
250 http://en.wikipedia.org/w/index.php?title=Levomepromazine&action=edit#
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • Only if clearly needed
Routes of
administration
Oral, seldom intramuscular
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailabilityapprox. 50 to 60%
MetabolismHepatic
Elimination half-life~ 20 hours
ExcretionIn feces and urine (metabolites), unchanged drug only 1%
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H24N2OS
Molar mass328.47 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Levomepromazine

Articles

Most recent articles on Levomepromazine

Most cited articles on Levomepromazine

Review articles on Levomepromazine

Articles on Levomepromazine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Levomepromazine

Images of Levomepromazine

Photos of Levomepromazine

Podcasts & MP3s on Levomepromazine

Videos on Levomepromazine

Evidence Based Medicine

Cochrane Collaboration on Levomepromazine

Bandolier on Levomepromazine

TRIP on Levomepromazine

Clinical Trials

Ongoing Trials on Levomepromazine at Clinical Trials.gov

Trial results on Levomepromazine

Clinical Trials on Levomepromazine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Levomepromazine

NICE Guidance on Levomepromazine

NHS PRODIGY Guidance

FDA on Levomepromazine

CDC on Levomepromazine

Books

Books on Levomepromazine

News

Levomepromazine in the news

Be alerted to news on Levomepromazine

News trends on Levomepromazine

Commentary

Blogs on Levomepromazine

Definitions

Definitions of Levomepromazine

Patient Resources / Community

Patient resources on Levomepromazine

Discussion groups on Levomepromazine

Patient Handouts on Levomepromazine

Directions to Hospitals Treating Levomepromazine

Risk calculators and risk factors for Levomepromazine

Healthcare Provider Resources

Symptoms of Levomepromazine

Causes & Risk Factors for Levomepromazine

Diagnostic studies for Levomepromazine

Treatment of Levomepromazine

Continuing Medical Education (CME)

CME Programs on Levomepromazine

International

Levomepromazine en Espanol

Levomepromazine en Francais

Business

Levomepromazine in the Marketplace

Patents on Levomepromazine

Experimental / Informatics

List of terms related to Levomepromazine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Levomepromazine (INN, BAN, USAN), also known as methotrimeprazine (common use in America; sold as Nosinan, Nozinan, Levoprome) is an phenothiazine neuroleptic drug. It is a low-potency antipsychotic (approximately half as potent as chlorpromazine) with strong analgesic, hypnotic and antiemetic properties that is primarily used in palliative care.[1][2]

Serious side effects include tardive dyskinesia, akathisia, abnormalities in the electrical cycle of the heart, low blood pressure and the potentially fatal neuroleptic malignant syndrome.[1][2]

As is typical of phenothiazine antipsychotics, levomepromazine is a "dirty drug", that is, it exerts its effects by blocking a variety of receptors, including adrenergic receptors, dopamine receptors, histamine receptors, muscarinic acetylcholine receptors and serotonin receptors.[1][2]

Medical uses

Levomepromazine is used for the treatment of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder. It should be used only with caution in the treatment of agitated depressions, as it can cause akathisia as a side effect, which could worsen the agitation.[1][2]

Levomepromazine is also used at lower doses for the treatment of nausea and insomnia.[1]

Levomepromazine is frequently prescribed and valued worldwide in palliative care medicine for its multimodal action, to treat intractable nausea or vomiting, and for severe delirium/ agitation in the last days of life. Palliative care physicians will commonly prescribe it orally or via subcutaneous syringe drivers in combination with more potent opiate analgesics such as Hydromorphone.[1][2]

Adverse effects

The most common side effect is akathisia.[2] Levomepromazine has prominent sedative and anticholinergic/sympatholytic effects (dry mouth, hypotension, sinus tachycardia, night sweats) and may cause weight gain.[2] These side effects normally preclude prescribing the drug in doses needed for full remission of schizophrenia, so it has to be combined with a more potent antipsychotic.[2] In any case, blood pressure and EKG should be monitored regularly.[2]

A rare but life-threatening side effect is neuroleptic malignant syndrome (NMS).[2] The symptoms of NMS include muscle stiffness, convulsions and fever.[2]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 Brayfield, A, ed. (13 December 2013). "Levomepromazine". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 12 May 2014.
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 Template:Cite isbn

Linked-in.jpg